I-STAT, COAGUCHEK XS PLUS, AND HEMOCHRON VERSUS REFERENCE LABORATORY INRS: PHARMACIST-MANAGED CLINICS

Authors

  • AHMAD AL-MEMAN Assistant Professor and Registered consultant clinical pharmacist , School of Medicine Uniazah, Qassim University, Saudi Arabia.

Keywords:

I-Stat, CoaguChek-XS Plus, Hemochron, Warfarin

Abstract

Objectives: The international normalized ratio (INR) is the primary measure used to determine the therapeutic effect of warfarin. I-Stat, CoaguChek-XS Plus, and Hemochron are the most frequently used point-of-care tests (POCTs); hence, we compared the results of each with our reference laboratory results.

Methods: Subjects were recruited during our clinic's annual evaluation phase for therapeutic optimization. Upon acceptance, an instant ï¬nger-stick or ï¬nger-prick test was performed as required in addition to venous blood sampling. Approximately 0.1–0.3 mL of blood was taken peripherally for the POCTs, whereas 3 mL was taken for the reference laboratory to measure the INR. Bland-Altman plots were used to analyze the data and test their agreement.

Results: A total of 180 blood samples were taken from 45 patients. The sample volumes for Hemochron were higher than for I-Stat and CoaguChek-XS Plus, and 70% of patients reported more pain for this method. While I-Stat has additional test options and does not require a ï¬nger stick, CoaguChek-XS Plus is the cheapest test in terms of the acquisition cost for the handset and strips. The INR estimated by the reference laboratory ranged from 1.1 to 8. The Bland-Altman plots revealed a good agreement between methods, with only 3–6 outliers in each plot. Of the samples, 6%, 6%, and 13% of the results were considered to be outside the clinically acceptable range (±0.5 INR) for I-Stat, CoaguChek-XS Plus, and Hemochron, respectively.

Conclusion: The results obtained using the three POCTs are in good agreement with the reference laboratory results.

 

Downloads

Download data is not yet available.

Author Biography

AHMAD AL-MEMAN, Assistant Professor and Registered consultant clinical pharmacist , School of Medicine Uniazah, Qassim University, Saudi Arabia.

Acting-Vice dean of Quality and Assurance, College of Medicine Uniazah, Qassim University

Coordinator of the anticoagulation clinic, Prince Sultan Cardiac Center, Buriadah, Qassim

References

Ageno W, Gallus A, Wittkowsky A, Crowther M, Hylek EM, Palareti G. The antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141 Suppl 2:e44S-e88S.

Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: Results of the J-RHYTHM registry. Circ J 2013;77:2264–70.

Health Quality Ontario. Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis. Ont Health Technol Assess Ser 2009;9:1–114.

Christensen TD, Larsen TB. Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. J Thromb Haemost 2009;10:251–60.

Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010;14(4):38-9.

Van Cott EM. Point-of-care testing in coagulation. Clin Lab Med 2009;29:543–53.

Perry SL, Samsa GP, Ortel TL. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. Thromb Haemost 2005;94:1196–202.

Wieloch M, Hillarp A, Strandberg K, Nilsson C, Svensson PJ. Comparison and evaluation of a point-of-care device (CoaguChek-XS Plus) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin. Thromb Res 2009;124:344–8.

Bardakci H, Altintas G, Faruk-Cicek O, Kervan U, Yilmaz S, Kaplan S, et al. Comparison of the Coagu Chek-XS Plus handheld coagulation analyzer and conventional laboratory methods measuring international normalized ratio (INR) values during the time to therapeutic range after mechanical valve surgery. J Card Surg 2013;28:254–7.

Nam MH, Roh KH, Pak HN, Lee CK, Kim YH, Lee KN, et al. Evaluation of the Roche Coagu Chek-XS Plus handheld coagulation analyzer in a cardiac outpatient clinic. Ann Clin Lab Sci 2008;38:37–40.

Williams VK, Griffiths AB. Acceptability of CoaguChek S and CoaguChek-XS Plus generated international normalised ratios against a laboratory standard in a paediatric setting. Pathol 2007;39:575–9.

Braun S, Watzke H, Hasenkam JM, Schwab M, Wolf T, Dovifat C, et al. Performance evaluation of the new CoaguChek-XS Plus system compared with the established CoaguChek system by patients experienced in INR self-management. Thromb Haemost 2007;97:310–4.

Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and clinical usefulness of the CoaguChek S and XS Point of Care devices when starting warfarin in a hospital outreach setting. Thromb Res 2009;123:909–13.

Torreiro EG, Fernandez EG, Rodriguez RM, Lopez CV, Nunez JB. Comparative study of accuracy and clinical agreement of the CoaguChek-XS Plus portable device versus standard laboratory practice in unexperienced patients. Thromb Haemost 2009;101:969–74.

Christensen TD, Larsen TB, Jensen C, Maegaard M, Sّrensen B. International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy. Thromb Haemost 2009;101:563–9.

Paioni P, Kroiss S, Kagi E, Bergstrasser E, Fasnacht M, Bauersfeld U, et al. Self-monitoring of oral anticoagulation therapy in children. Acta Haematol 2009;122:58–63.

Bauman ME, Black KL, Massicotte MP, Bauman ML, Kuhle S, Howlett-Clyne S, et al. Accuracy of the CoaguChek-XS Plus for point-of-care international normalized ratio (INR) measurement in children requiring warfarin. Thromb Haemost 2008;99:1097–103.

Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995;346:1085–7.

Gauss T, Hamada S, Jurcisin I, Dahmani S, Boudaoud L, Mantz J, et al. Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron Signature Elite® during acute haemorrhage. Br J Anaesth 2013;112:514–20.

Racioppi L, Quinart A, Biais M, Nouette-Gaulain K, Revel P, Sztark F. Validation of a bedside activated clotting time test (Hemochron Jr II Signature) with low dose heparin therapy. Anaesthesia 2009;64:430–4.

Maddox JM, Bogo PH, McGregor E, Pippard MJ, Kerr R. Quality assurance for point-of-care testing of oral anticoagulation: a large-scale evaluation of the hemochron junior signature microcoagulation system. Int J Lab Hematol 2009;31:142–50.

Peٌa JA, Lewandrowski KB, Lewandrowski EL, Gregory K, Baron JM, Van Cott EM. Evaluation of the I-Stat point-of-care capillary whole blood prothrombin time and international normalized ratio: comparison to the Tcoag MDAII coagulation analyzer in the central laboratory. Clin Chim Acta 2012;413:955–9.

Boehlen F, Reber G, de Moerloose P. Agreement of a new whole-blood PT/INR test using capillary samples with plasma INR determinations. Thromb Res 2005;115:131–4.

Donaldson M, Sullivan J, Norbeck A. Comparison of international normalized ratios provided by two point-of-care devices and laboratory-based venipuncture in a pharmacist-managed anticoagulation clinic. Am J Health Syst Pharm 2010;67:1616–22.

Published

01-01-2015

How to Cite

AL-MEMAN, A. “I-STAT, COAGUCHEK XS PLUS, AND HEMOCHRON VERSUS REFERENCE LABORATORY INRS: PHARMACIST-MANAGED CLINICS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 1, Jan. 2015, pp. 284-8, https://journals.innovareacademics.in/index.php/ijpps/article/view/3344.

Issue

Section

Original Article(s)